BI 706321

DRUG5 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim

Conditions

Crohn DiseaseCrohn`s Disease (CD)Healthy

Phase 1

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321

CompletedNCT03971695

Boehringer IngelheimHealthy

Start: 2019-06-18End: 2020-12-04Updated: 2025-09-18

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood

CompletedNCT04714073

Boehringer IngelheimHealthy

Start: 2021-02-11End: 2021-04-30Updated: 2025-09-12

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

TerminatedNCT05183360

Boehringer IngelheimHealthy

Start: 2022-02-07End: 2024-08-08Updated: 2025-09-23

Phase 2

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

TerminatedNCT04978493

Boehringer IngelheimCrohn Disease

Start: 2021-12-02End: 2024-08-08Updated: 2025-09-04

A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment

CompletedCTIS2024-512756-38-00

Boehringer Ingelheim International GmbHCrohn`s Disease (CD)

Start: 2022-02-17End: 2024-08-08Target: 27Updated: 2024-08-05